Tag Archives: FT536

Latest NK Cell Therapy Advances Discussed in a Panel Session; Fate Tx Presents Preclinical Updates for Two iPSC-derived CAR-NKs; AACR 2021 Day 5

On the fifth day of AACR 2021 Week I, two key preclinical CAR-NK updates were reported from Fate Therapeutics, while the latest NK cell engineering approaches were reviewed during a panel discussion. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.